Company intelligence / Profile preview
Renovion
Chapel Hill, North Carolina, United Statesrenovion.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Renovion recently announced positive top-line results from Phase 2 CLIMB study of ARINA-1 (RVN-301) in patients with Non-Cystic Fibrosis Bronchiectasis on May 2, 2024. The study showed improved quality of life and mucus biomarkers in bronchiectasis patients. The company is also conducting a Phase 3 trial for ARINA-1 in lung transplant patients with BOS.
- Therapeutic areas
- Pulmonology
- Modalities
- Nebulized therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
COPD Foundation
Beyond the preview
Go deeper on Renovion.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Renovion.